Weight loss
The first GLP-1 drug, derived from Gila monster venom (Byetta, Bydureon) — FDA-approved for type 2 diabetes in daily and weekly forms.
Start here
Exenatide is a diabetes medicine sold as Byetta and Bydureon — the first drug in the GLP-1 (a gut hormone that tells your brain you're full) class, medicines that copy a gut hormone to help control blood sugar, to reach the market back in 2005. It was developed from a protein found in Gila monster venom. It is FDA-approved for type 2 diabetes, available as a twice-daily or once-weekly injection 67, and produces modest weight loss of roughly 2 to 5 kg 4. A trial of 14,752 patients confirmed its cardiovascular safety 1.
Exenatide copies a hormone your gut releases after meals. When it docks onto its target on the pancreas, your body releases insulin — but only when blood sugar is actually high, so it rarely pushes sugar too low. It also quiets glucagon, a hormone that tells the liver to dump sugar into the blood, slows how fast your stomach empties, and signals your brain that you are full. The original molecule was found in Gila monster venom, and the drug comes as a twice-daily shot (Byetta) or a once-weekly one (Bydureon).
Exenatide is a lab-made peptide of 39 amino acids (protein building blocks), identical to exendin-4, a natural GLP-1 receptor agonist (a molecule that copies the gut hormone GLP-1 (a gut hormone that tells your brain you're full)) found in the venom of the Gila monster (Heloderma suspectum). It matches human GLP-1 by 53% but has one key swap, Gly2 in place of Ala2. This swap stops DPP-4 (an enzyme that destroys GLP-1) from breaking it down. The half-life (time for half the drug to clear) is 2.4 hours with Byetta, or ~7 weeks with Bydureon, which uses poly(D,L-lactide-co-glycolide) microspheres (tiny slow-dissolving beads). Exenatide binds to and activates the GLP-1 receptor (Kd ~136 pM, ~4-fold tighter than native GLP-1) on pancreatic beta cells (insulin-making cells), so insulin is released only when blood sugar is high. It lowers glucagon (a hormone that raises blood sugar) after meals, slows stomach emptying, and makes you feel full by switching on GLP-1 receptors in the hypothalamus (the brain's appetite center).
Evidence check
Well studied in people
This has been through large human trials — the strongest kind of evidence. Scientists have tested it on many people and measured what actually happened.
Every numbered marker on this page links to one of the 7 sources at the bottom.
Blood Sugar Control
Works like a key that unlocks your body's natural insulin release, but only when blood sugar is high, which helps prevent dangerous lows.
Weight Loss
Slows down digestion and sends fullness signals to your brain, helping most people lose around 5 to 11 pounds over time.
Heart Safety
A major study of nearly 15,000 people showed it doesn't increase heart attack or stroke risk, even in those with heart disease.
The most-asked question
The research-reported range is 10 mcg, once weekly. Studies used different doses for different situations — find yours:
Type 2 diabetes, Glycemic control
5 mcg
FDA-labeled starting dose for immediate-release Byetta to assess tolerability before escalating 6.
Type 2 diabetes, Glycemic control
10 mcg
FDA-labeled maintenance dose for immediate-release Byetta after 1 month at the starting dose 6.
Type 2 diabetes, Weekly dosing convenience
2 mg
Extended-release exenatide (Bydureon) FDA-labeled at 2 mg once every 7 days; convenient weekly alternative to twice-daily dosing 7. Once-weekly exenatide has cardiovascular outcome data 1.
The ceiling: 10 (as determined by your healthcare provider based on individual response and tolerance)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Exenatide:
Add the recommended volume of bacteriostatic water to the Exenatide vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Exenatide is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Exenatide's recorded schedule.
Injection sites & technique
Subcutaneous (under the skin) injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Timing
Administer Exenatide at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
Exenatide injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
Exenatide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
Most frequent adverse effect — 44% with Byetta, 6 25–30% with Bydureon. Typically mild to moderate, most pronounced during initial weeks and dose escalation 6.
What to do Gradual dose titration (5→10 mcg over 1 month for Byetta). Eat smaller meals. Avoid fatty foods. Nausea generally improves with continued use. Bydureon has lower nausea rates than Byetta.
Vomiting in 10–15% and diarrhea in 12–15% of patients. GI effects are dose-related and more common with the immediate-release formulation 6.
What to do Stay well hydrated. If severe, temporarily maintain current dose rather than escalating. Consider switching to Bydureon for better GI tolerability.
Subcutaneous (under the skin) nodules at injection sites occur in 5–10% of Bydureon users due to the microsphere depot formulation. 7 Usually painless and self-resolving.
What to do Rotate injection sites regularly. Nodules typically resolve over weeks as microspheres are absorbed. No treatment usually required.
Lower appetite (helpful for weight management) and constipation (10–20%) are common stomach and gut effects of the drug acting on GLP-1 (a gut hormone that tells your brain you're full) receptors (docking points) 6.
What to do Appetite reduction is expected and therapeutic. Constipation managed with adequate fiber and fluid intake.
Worth knowing about, but most people never see these.
Rare as monotherapy (<5%) due to glucose-dependent mechanism. 6 Risk increases significantly when combined with sulfonylureas or insulin (5–10%).
What to do Reduce sulfonylurea or insulin dose when initiating exenatide. Monitor blood glucose regularly, especially during first weeks of combination therapy.
Rare, but if any of these happen, stop and contact a medical professional.
Acute pancreatitis reported in 0.2% of EXSCEL participants. FAERS pharmacovigilance data shows significant pancreatitis signal with exenatide. 3 Potentially life-threatening.
What to do Discontinue exenatide immediately if pancreatitis suspected (severe persistent abdominal pain). Monitor amylase/lipase. Do not restart after confirmed pancreatitis.
Acute kidney injury reported rarely, typically associated with severe dehydration from GI side effects (vomiting, diarrhea). Exenatide is renally cleared 6.
What to do Ensure adequate hydration. Monitor renal function. Contraindicated in eGFR <15. Use with caution in moderate renal impairment (eGFR 15–29).
Week by week
Is it right for you?
Exenatide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
May be used together under medical guidance.
May be used together under medical guidance.
May be used together under medical guidance.
Generally safe to take alongside Exenatide. Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Exenatide is particularly well-suited for individuals focused on type 2 diabetes patients inadequately controlled on metformin seeking add-on therapy with weight loss benefit. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 5.
Exenatide is particularly well-suited for individuals focused on patients preferring once-weekly dosing convenience (bydureon 2 mg) over daily injections for improved adherence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 7.
Exenatide is particularly well-suited for individuals focused on overweight or obese type 2 diabetes patients (bmi >27) requiring glycemic control (keeping blood sugar steady) without weight gain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 4.
Exenatide is particularly well-suited for individuals focused on patients with established cardiovascular disease who need a glp-1 (a gut hormone that tells your brain you're full) ra with demonstrated cardiovascular safety. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Exenatide is an FDA-approved GLP-1 receptor agonist (it switches on the GLP-1 (a gut hormone that tells your brain you're full) docking points) with post-market safety data spanning 15+ years, though some safety concerns have emerged. Nausea affects 30-45% of patients, 6 rises with dose, and typically improves within 1-2 weeks but can lead to 5% of patients stopping treatment. Pancreatitis (inflamed pancreas) risk, while rare (0.1-0.2%), is increased, and the drug must not be used by anyone with a history of acute pancreatitis. Benign thyroid C-cell adenomas (non-cancerous thyroid growths) were seen in rats at all exenatide doses in a 104-week cancer-risk study, but this appears only in the Nonclinical Toxicology section: the immediate-release label (Byetta) carries no boxed warning and does not rule out use in people with medullary thyroid cancer or MEN 2 (an inherited condition that causes tumors in hormone glands). That restriction belonged to extended-release Bydureon, which no longer has a current US label. Acute kidney injury has been reported in 0.3-1% of patients, particularly with NSAIDs or ACE inhibitors taken at the same time. Low blood sugar risk is minimal when used alone but increases substantially when combined with insulin or sulfonylureas (diabetes pills that push the body to make more insulin).
Exenatide was studied in Phase 3 trials (DURATION program) for type 2 diabetes with long-term safety data spanning 5-10 years in individual trials. Multiple post-market surveillance studies and comparative efficacy trials with other GLP-1 (a gut hormone that tells your brain you're full) agonists (particularly semaglutide) 35 provide evidence of its safety profile. The preclinical (animal or lab studies, not human trials) thyroid C-cell findings and post-market pancreatitis reports have led to specific monitoring recommendations and contraindication protocols.
Keeping it good
Store Exenatide in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, Exenatide should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2017
In a 14,752-patient study, once-weekly exenatide was safe for the heart (matching placebo) but did not do statistically better than placebo. It showed strong heart safety, even though it did not beat placebo.
Holman RR, Bethel MA, Mentz RJ, et al.
2017
Research (2017) on exenatide contributes important scientific knowledge about its biological and pharmacological properties.
Mentz RJ, Bethel MA, Gustavson S, et al.
2024
Clinical data (2024) establishes the safety profile and tolerability of exenatide in human subjects.
Osei SP, Akomaning E, Florut TF, et al.
2022
Research (2022) demonstrates exenatide's efficacy in clinical treatment and therapeutic applications.
Zhang J, Xian TZ, Teng Y, et al.
2025
Research (2025) demonstrates exenatide's efficacy in clinical treatment and therapeutic applications.
Katz G
2024
FDA label: start Byetta at 5 mcg injected under the skin twice daily, within 60 minutes before the two main meals; may raise to 10 mcg twice daily after 1 month based on response.
U.S. Food and Drug Administration
2024
Carries the boxed warning (the FDA's strongest warning) for thyroid C-cell tumors; must not be used with a personal or family history of medullary thyroid carcinoma (MTC, a thyroid cancer) or MEN 2 (an inherited cancer syndrome). Trials 1-2 adverse reactions: injection site nodule (lump) 10.5%, nausea 8.2% (usually decreased over time). Cited via RxList reproduction because the product was withdrawn in the US and neither accessdata.fda.gov (prior URL 404), openFDA, nor DailyMed hosts the label any longer.
U.S. Food and Drug Administration
If this isn't the right fit
Your questions
Dr. John Eng, an endocrinologist (hormone doctor) at the Miami VA Medical Center, discovered exendin-4 in Gila monster (Heloderma suspectum) venom in 1992. He was studying how this lizard keeps its blood sugar steady during long fasts between rare meals. Exendin-4 turned out to be a potent GLP-1 receptor agonist (it switches on the same docking points as the natural GLP-1 (a gut hormone that tells your brain you're full) hormone). Unlike human GLP-1, it resists the DPP-4 enzyme that rapidly breaks the natural hormone down, which made it an ideal drug candidate for type 2 diabetes.
Both contain exenatide but differ in form and dosing. Byetta is immediate-release exenatide (5–10 mcg injected twice daily before meals) that controls blood sugar spikes after meals. Bydureon uses tiny slow-release beads (poly(D,L-lactide-co-glycolide) microspheres) to deliver 2 mg of exenatide once weekly, giving steady action on GLP-1 (a gut hormone that tells your brain you're full) receptors (the docking points the drug acts on), with less nausea and easier day-to-day use.
EXSCEL enrolled 14,752 type 2 diabetes patients (73% with prior cardiovascular disease) across 688 sites in 35 countries. After a median 3.2 years of follow-up, once-weekly exenatide was noninferior to placebo for cardiovascular safety (MACE HR 0.91, 95% CI 0.83–1.00). While it met the safety endpoint, it did not demonstrate statistically significant cardiovascular superiority (P=0.06 for superiority).
Yes, Bydureon BCise was approved in 2020 for pediatric patients aged 10–17 years with type 2 diabetes as an adjunct to diet and exercise. This makes exenatide one of the few GLP-1 receptor agonists (drugs that mimic the gut's fullness hormone) with an approved pediatric indication.
Exenatide was the first drug of its class (GLP-1 (a gut hormone that tells your brain you're full) RAs) and has the longest safety track record. However, newer drugs like semaglutide lower HbA1c (3-month average blood sugar) and weight more. Meta-analyses (studies that pool many trials) show semaglutide > dulaglutide > exenatide for overall effect. Exenatide's advantages include its established safety record, two forms (twice-daily and weekly), and the approved use in young people for Bydureon BCise.
Byetta (immediate-release) causes more nausea (~44%) because it produces fast, high peaks of the drug in your blood that strongly activate GLP-1 (a gut hormone that tells your brain you're full) receptors (the docking points the drug acts on) in the area postrema (the brain's nausea center). Bydureon (extended-release) has lower nausea rates (25–30%) because its slow-release beads give a gradual, steady release without sharp peaks. Newer long-acting drugs in this class also tend to cause less nausea for similar reasons.
7 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Exenatide research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Talk to a clinician before taking anything.
PeptideGeek